So the obviousness patents go back into the orange book and are considered valid again?
What happens if some other drug manufacturer tries to sell gVascepa which prompts a lawsuit by Amarin? Is the defendant not allowed to cite Judge Du's ruling?
Hi Marjac, this Vacatur scenario would seem to be the best type of settlement but has to be agreed to by both R and H collectively. What is a sensible $ amount and change in time frame for pre 2029 to market agreement vs. binary appeals court decision? Maybe Teva and Apotex are tells that we can’t quite decipher currently?